Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 22,242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Opiate Addiction
Interventions: 6β-Naltrexol escalating doses from 0.05-0.5 mg IV; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Newport Beach, California • San Diego, California • San Francisco, California + 20 more

Conditions: Microscopic Hematuria
Interventions: Premarin vaginal estrogen cream, Placebo vaginal cream; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy
Interventions: BioDFence G3 Placental Tissue Membrane, Robot-Assisted Radical Prostatectomy; Biological · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HCV Infection
Interventions: ABT-450, ritonavir, Placebo for ABT-450, Placebo for ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Oral Contraceptive, Loestrin 1.5/30; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions: Dexamethasone, 0.4mg, Prednisone acetate, Control; Drug · Other
Lead sponsor: Warrenville Eyecare; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Warrenville, Illinois

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 18,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 202
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more

Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions: Camoteskimab, Placebo; Drug
Lead sponsor: Apollo Therapeutics Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 30
States / cities: Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more

Conditions: Osteoarthritis
Interventions: Active Device (Torino II), Sham Device (Torino II); Device
Lead sponsor: Center for Joint Surgery and Sports Medicine, Maryland; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Hagerstown, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: HIP2B, Placebo; Drug
Lead sponsor: CureDM; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Stroke Hemorrhagic
Interventions: fMRI; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 22 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Medication Adherence
Interventions: Increasing Medication Adherence through Physician Incentives and Messaging; Other
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 65 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Obesity, Cardiovascular Diseases
Interventions: Naltrexone HCl/Bupropion HCl ER, Placebo; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 139
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more

Conditions: HIV Infections, Alcoholism
Interventions: Brief alcohol intervention based on Project Treat, Standard care; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: SARS-CoV 2
Interventions: Tocilizumab, Placebos; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Newton, Massachusetts

Conditions: Nocturia, Daytime Sleepiness
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Epilepsy
Interventions: Vitamin E; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more

Conditions: Pain, Postoperative, Cardiac Surgery
Interventions: PECS2 block, Ropivacaine 0.5% Injectable Solution, Lidocaine Epinephrine, Dexmedetomidine 0.004 MG/ML; Procedure · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Asthma, Allergic
Interventions: REGN3500, Dupilumab, Placebo, Fluticasone propionate; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: COVID-19, ARDS
Interventions: SOC plus 15mg/kg EB05 IV, SOC plus Placebo IV; Biological · Other
Lead sponsor: Edesa Biotech Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Fresno, California • Fullerton, California • Coral Gables, Florida + 4 more

Conditions: Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions: Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids; Drug · Procedure
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Single Ventricle Defect
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Months to 10 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Dextenza With ILUX for Treatment of MGD

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Use of Pulsed Electromagnetic Fields for Postoperative Knee Pain

Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

Functional MRI and DTI Analysis of Post VNS Therapy Rehab Changes

Increasing Medication Adherence Through Physician Incentives and Messaging

Naltrexone/Bupropion Cardiovascular Outcomes Study

Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women

Efficacy of Tocilizumab on Patients With COVID-19

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

Pectoral Nerves Block to Relieve Post-sternotomy Pain After Cardiac Surgery

Study of REGN3500 and Dupilumab in Patients With Asthma

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

A Study With Imlifidase in Anti-GBM Disease

Cerebral Blood Flow in Single Ventricles Throughout Staged Surgical Reconstruction